Education
About Us
Working with TipRanks
Follow Us
Pharmaron Beijing Co., Ltd. Class H (DE:17Q1)
FRANKFURT:17Q1
17Q1 Stock Chart & Stats
€2.56
-€0.04(-2.45%)
At close: 4:00 PM EST
€2.56
-€0.04(-2.45%)
Day’s Range― - ―
52-Week Range€1.31 - €3.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.15B
Enterprise Value€49.36B
Total Cash (Recent Filing)€2.28B
Total Debt (Recent Filing)€6.39B
Price to Earnings (P/E)20.7
Beta0.75
Next Earnings
Mar 30, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding359,977,870
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio13.20
Price to Book (P/B)1.74
Price to Sales (P/S)1.93
P/FCF Ratio44.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated CRDMO Business ModelAn end-to-end CRDMO model creates durable demand as clients outsource from discovery through manufacturing. That breadth increases stickiness, enables multi-stage contracts as programs progress, and diversifies revenue sources, supporting steady long-term service demand and client retention.
Sustained Revenue ExpansionConsistent top-line growth (mid-teens on recent metric and material scaling over the cycle) signals persistent client demand and successful business development. Durable revenue expansion supports capacity utilization, strategic reinvestment, and a pathway to larger, longer-duration development and manufacturing contracts.
Improved Leverage And Growing EquityMarked reduction in leverage and steady equity growth enhances financial flexibility and resilience. Lower debt-to-equity reduces refinancing and liquidity risk, enabling sustained capex, strategic investments or deal activity without overburdening cash flow during industry cycles.
Bears Say
Margin Compression And Earnings Step-DownSignificant margin erosion over the cycle materially reduces profitability per revenue dollar. Lower net margins and a step-down in earnings suggest structural pressure (pricing, mix, or cost increases) that can persist, weakening internal cash generation and long-run returns unless operational efficiencies are regained.
Volatile And Subscale Free Cash FlowIrregular and relatively low free cash flow versus earnings constrains the firm's ability to self-fund growth, pay down debt or return capital. Persistent FCF volatility—driven by working-capital swings or reinvestment—raises dependence on external funding and increases long-term financial risk.
Eroding Return On EquityDeclining ROE indicates new invested capital is delivering weaker returns than prior periods. If sustained, lower profitability on a larger equity base limits shareholder value creation, signals potential competitive or execution challenges, and reduces the leverage benefit from balance-sheet expansion.
Pharmaron Beijing Co., Ltd. Class H News
17Q1 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was €1.31 and its highest was €3.24 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is €6.15B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Mar 30, 2026 which is in 35 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Oct 28, 2025. The company reported €0.029 earnings per share for the quarter, missing the consensus estimate of €0.03 by >-€0.001.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Overvalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H does not currently pay dividends.
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.03.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of €0.029 in its last earnings report, missing expectations of €0.03. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in DE:17Q1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
10.94%
Trailing 12-Months
Asset Growth
2.48%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---